Current Report Filing (8-k)
December 27 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 20, 2017
Arrowhead Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-21898
|
|
46-0408024
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
225 South Lake Avenue, Suite 1050, Pasadena, CA 91101
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code
(626) 304-3400
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b)
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4
(c) under the Exchange Act (17 CFR
240.13e-4(c)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
Election of William Waddill as a Director
At the
recommendation of the Nomination Committee, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the Company) elected William Waddill as an independent director of the Company with a term beginning effective January 1, 2018.
On December 20, 2017, Mr. William Waddill accepted and appointment to the Board of Directors of Arrowhead Pharmaceutical, Inc. It is anticipated that Mr. Waddill will serve on the Audit, Compensation and Nomination Committees.
Mr. Waddills compensation will consist of cash compensation of $52,500 and a grant of 25,000 restricted stock units that will vest on the one year
anniversary of the grant date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 27, 2017
|
|
|
ARROWHEAD PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Kenneth Myszkowski
|
|
|
Kenneth Myszkowski
|
|
|
Chief Financial Officer
|
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024